Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsAvadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Ophthalmology in 2025: Year in Review
Increases in Physician Attrition Rates Could Worsen Shortages
Hormonal Disorders in 2025: Year in Review
1.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
2.
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
3.
iPSC-based vaccines: A new hope for preventing and treating colorectal cancer
4.
Study sets benchmark for treatment of advanced cervical cancer
5.
Racial differences seen in epigenetic age acceleration in childhood cancer survivors
1.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
2.
Radiation in Oncology: Advances, Applications, and Accessibility
3.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
3.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge